Case Number:

IPR2023-00724

Case Type:

IPR

Status:

Trial Instituted

Petitioner:

Mylan Pharmaceuticals Inc. et al.

1. Filed: March 16, 2023 00:00

   Coverage

   1. October 07, 2024

      Mylan, Novo Nordisk Settle Ozempic Patent Dispute

      Mylan Pharmaceuticals and Novo Nordisk have asked the Patent Trial and Appeal Board to terminate Mylan's request to review whether a patent covering Novo Nordisk's blockbuster diabetes and weight-loss drug Ozempic holds up, telling the board the two sides have resolved their dispute.

   2 other articles on this case. View all »

   ---

   Stay ahead of the curve

   In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

   
   

   • Search PTAB cases and full-text documents.
   • Download filings with the U.S. Patent & Trademark Office’s Patent Trial & Appeal Board.
   • Set up alerts on new cases, follow ongoing cases, track new decisions and so much more!

   TRY LAW360 FREE FOR SEVEN DAYS

   View the PTAB case documents

   Already a subscriber? Click here to login